Previous 10 | Next 10 |
2023-08-15 09:25:20 ET Summary Natera specializes in cfDNA technology, achieving 31.9% revenue growth in Q2 2023 and raising their annual outlook. Despite strong growth, Natera faces challenges with profitability, annual cash burn, and existing debts. Considering growth prospe...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-04 11:15:26 ET Shares of Natera (NASDAQ: NTRA) were soaring 18.7% higher at 11:04 a.m. ET on Friday. The big gain came after the DNA testing company announced its second-quarter results following the market close on Thursday. Natera reported Q2 revenue of $261.4 million,...
2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...
2023-08-03 22:08:04 ET Natera, Inc. (NTRA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Michael Brophy – Chief Financial Officer Steve Chapman – Chief Executive Officer Solomon Moshkevich – General Manager-O...
2023-08-03 16:53:46 ET Natera press release ( NASDAQ: NTRA ): Q2 GAAP EPS of -$0.97 beats by $0.11 . Revenue of $261.4M (+31.9% Y/Y) beats by $19.87M . Outlook: Natera is raising its expectations for 2023 total revenue from $995 million to $1.015 billion to...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 ...
2023-08-02 17:35:58 ET Natera ( NASDAQ: NTRA ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, after market close. The consensus EPS Estimate is -$1.10 and the consensus Revenue Estimate is $241.53M (+21.9% Y/Y). Over the last 1 year, NTRA has b...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of t...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...